Biological Safety Testing – Global Market Size, Share & Trends Analysis & Forecast: 2018 to 2024 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Biological
Safety Testing Market Size, Share & Trends Analysis Report By Product,
By Application (Vaccines & Therapeutics, Gene Therapy, Stem Cell), By
Test, By Region, And Segment Forecasts, 2018 – 2024” report has
been added to ResearchAndMarkets.com’s offering.

The global biological safety testing market size is expected to reach
USD 5.54 billion by 2024, registering a CAGR of 12.2% during the
forecast period.

The market is predominantly driven by increasing influx of biologics,
which raises the requirements of highly efficient biological safety
testing tools. Rising disease burden is expected to be a major cause for
high production of biologics, thereby contributing toward market growth.

Increasing prevalence of lifestyle-associated chronic diseases such as
cancer and diabetes serves as a key contributing factor toward
increasing drug development and their subsequent commercialization. This
is presumed to raise the need to scrutinize and ensure safety of
targeted and specialized therapies, evaluate their outcomes, and
circumvent probable shortcomings. As a consequence of high manufacturing
intensity, pharmaceutical and biotechnology companies are increasingly
incorporating biological safety testing tools to produce highly potent
and contamination-free biologics to cater to the large population
suffering from target diseases.

Viral safety testing is proving to be one of the primary concerns of
most companies as it is a critical component of chemistry,
manufacturing, and control of biologics. This presents the market with
several potential growth opportunities in future.

Laboratory-based contaminations have stimulated the development and
refinement of workstations by incorporating biological safety tools.
Need to work with tissue cultures, maintain sterility of cell lines, and
minimize cross-contamination has contributed to concerns regarding
product integrity.

The aforementioned factors are responsible for raising concerns of
public organizations. Consistent intervention by government healthcare
organizations to implement good manufacturing practices and subsequent
testing and control at every production stage is believed to widen the
growth opportunities of the market.

Further key findings from the study suggest:

• By product, reagents and kits accounted for the largest share of over
  42% in 2015 as they form major components and are extensively used in
  research and clinical laboratories
• The instruments segment, on the other hand, is expected to witness a
  lucrative CAGR of 13.2% during the forecast period due to rising
  demand from various clinical and research laboratories
• Based on application, the vaccine segment is expected to exhibit a
  CAGR of 12.9% during the forecast period, which can be predominantly
  attributed to significant increase in disease outbreaks over the years
• Bioburden tests are expected to grow at a lucrative rate throughout
  the forecast period owing to high adoption rate to determine bioburden
  limits in wide-ranging biologics and medical devices
• North America dominated the global market with over 36% in 2015 owing
  to high R&D investments in biotechnology
• The Asia Pacific regional market is anticipated to exhibit a strong
  CAGR of over 13.1% during the forecast period.

Key Topics Covered

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

1.3. List of Data Sources

Chapter 2. Executive Summary

Chapter 3. Market Snapshot

Chapter 4. Market Variables, Trends & Scope

4.1. Market segmentation & scope

4.2. Market Driver Analysis

4.2.1. Rising number of government initiatives and recommendations

4.2.2. Increasing production of new biologics due to high disease burden

4.2.3. Rising number of pharmaceutical and biotechnological companies

4.2.4. High R&D investments in clinical research and life sciences
research

4.3. Market Restraint Analysis

4.3.1. Time consuming approval process

4.4. Penetration & growth prospect mapping

4.5. Biological Safety Testing – SWOT Analysis, By Factor (political &
legal, economic and technological)

4.6. Industry Analysis – Porter’s

Chapter 5. Market Categorization 1: Product Estimates & Trend Analysis

5.1. Biological safety testing market: Product movement analysis

5.2. Reagents & kits

5.3. Instruments

5.4. Others

Chapter 6. Market Categorization 2: Application Estimates & Trend
Analysis

6.1. Biological safety testing market: Application movement analysis

6.2. Stem cell

6.3. Tissue & tissue-based products

6.4. Gene therapy

6.5. Blood & blood-based products

6.6. Vaccines & therapeutics

Chapter 7. Market Categorization 3: Test Estimates & Trend Analysis

7.1. Biological safety testing market: Test movement analysis

7.2. Sterility tests

7.3. Cell line authentication & characterization tests

7.4. Bioburden tests

7.5. Adventitious agent detection tests

7.6. Residual host contamination detection tests

7.7. Others

Chapter 8. Market Categorization 4: Regional Estimates & Trend Analysis,
By Product, Application & Test

8.1. Biological safety testing market share by region, 2015 & 2024

8.2. North America

8.3. Europe

8.4. Asia Pacific

8.5. Latin America

8.6. MEA

Chapter 9. Competitive Landscape

9.1. Strategy framework

9.2. Market participation categorization

9.3. Company Profiles

9.3.1. Charles River Laboratories International Inc.

9.3.2. BSL Bioservice Scientific Laboratories GmbH

9.3.3. Lonza

9.3.4. Cytovance Biologics

9.3.5. Sigma Aldrich Corporation

9.3.6. Merck Mellipore

9.3.7. SGS S.A.

9.3.8. Toxikon Inc.

9.3.9. Wuxi Pharmatech (Cayman) Inc.

9.3.10. Avance Biosciences

For more information about this report visit https://www.researchandmarkets.com/r/womxyb

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Biopharmaceuticals